Millions of horse owners worldwide are anticipating a breakthrough in the treatment of equine gastric disease, a prevalent condition among high-performance horses, particularly in racing and endurance riding. The University of South Australia, in collaboration with Luoda Pharma, has developed a revolutionary long-acting injectable medicine that offers a more efficient alternative to the current standard oral paste treatment.
Professor Sanjay Garg, a pharmaceutical scientist at UniSA, highlights the limitations of the existing oral paste treatment, emphasizing its daily administration and relatively low effectiveness. The new injectable formulation of omeprazole has garnered significant success in Europe, becoming the preferred choice of treatment for many veterinarians due to its faster healing properties.
Gastric disease affects a substantial percentage of racehorses and high-level endurance horses, with current treatments like histamine antagonists and oral proton pump inhibitors showing varying degrees of efficacy. The innovative sustained-release injection developed by UniSA and Luoda Pharma aims to address the shortcomings of traditional treatments by providing extended acid suppression, leading to accelerated healing in affected horses.
Dr. Stephen Page from Luoda Pharma underscores the prolonged acid suppression achieved by the new injectable form of omeprazole, with clinical data indicating healing within a significantly shorter timeframe compared to conventional therapies. This advancement not only enhances the well-being of horses but also alleviates the economic burden on owners and the equine industry by improving performance and reducing treatment costs.
The global reach of this groundbreaking equine product delivery technology holds immense promise for the enhancement of horse health and welfare on a large scale. With an estimated 58 million horses worldwide, the potential impact of this novel treatment is profound, offering a ray of hope for both horses and their owners.
Luoda Pharma, the commercial rights holder of this innovative medicine, plans to pursue global registration to ensure widespread access for horses in need. The patent for this transformative technology underscores the significance of this collaborative effort between academia and industry in advancing veterinary medicine.
Professor Sanjay Garg’s expertise in drug delivery systems and veterinary formulations, coupled with Luoda Pharma’s commitment to addressing unmet needs in animal health, exemplifies the synergy between scientific research and practical application in driving positive outcomes for the equine industry.
This pioneering development not only represents a major milestone in equine healthcare but also serves as a testament to the power of research collaboration in revolutionizing treatment options for animals. The collective efforts of academia and industry have the potential to reshape the landscape of veterinary medicine, offering new hope and healing for horses worldwide.
📰 Related Articles
- Revolutionary Motorcycle Rear-Facing Camera with Head-Up Display Unveiled
- Innovative Focused Ultrasound Treatment Program for Movement Disorders Unveiled
- Xolair Approval Marks Milestone in Food Allergy Treatment Innovations
- Watain’s Seventh Album: The Agony and Ecstasy Unveiled
- Warragul Cup Day: Harness Racing Excitement Unveiled